Cargando…
Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer
THE PURPOSE: Assessing the accuracy of multi parametric magnetic resonance (mp-MRI) after application of PI-RADS V2 for diagnosis of prostate cancer as comparison to pathological results of trans rectal ultra-sound (TRUS) guided biopsy. PATIENTS AND METHODS: 138 prostatic lesions in 23 patients were...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369010/ https://www.ncbi.nlm.nih.gov/pubmed/28377946 http://dx.doi.org/10.1016/j.ejro.2017.02.001 |
_version_ | 1782518044088598528 |
---|---|
author | Dola, Eman F. Nakhla, Osama L. Genidi, Eman A.SH |
author_facet | Dola, Eman F. Nakhla, Osama L. Genidi, Eman A.SH |
author_sort | Dola, Eman F. |
collection | PubMed |
description | THE PURPOSE: Assessing the accuracy of multi parametric magnetic resonance (mp-MRI) after application of PI-RADS V2 for diagnosis of prostate cancer as comparison to pathological results of trans rectal ultra-sound (TRUS) guided biopsy. PATIENTS AND METHODS: 138 prostatic lesions in 23 patients were retrospectively assessed and analyzed with Trans rectal ultra-sound (TRUS) guided biopsy results. Those patients underwent multi parametric magnetic resonance (mp-MRI) with application of PI-RADS V2 reporting system. The sensitivity, specificity, validity, negative predictive value and positive predictive value were calculated for PI-RADS V2 reporting system compared to biopsy-proven pathological results. RESULTS: 92 out of 138 lesions were positive for Peripheral zone cancer prostate. PI-RADS V2 reporting system proved 88.04% sensitive & 93.4% specific for diagnosis of prostate cancer with negative predictive value & positive predictive value of 100%. CONCLUSION: Our results proved that mp-MRI of prostate using PI-RADS v2 scoring system had high sensitivity and specificity in diagnosis of prostate cancer and PI-RADS V2 scoring system using mp-MRI is recommended as a non-invasive diagnostic tool compared to TRUS guided biopsy. |
format | Online Article Text |
id | pubmed-5369010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-53690102017-04-04 Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer Dola, Eman F. Nakhla, Osama L. Genidi, Eman A.SH Eur J Radiol Open Article THE PURPOSE: Assessing the accuracy of multi parametric magnetic resonance (mp-MRI) after application of PI-RADS V2 for diagnosis of prostate cancer as comparison to pathological results of trans rectal ultra-sound (TRUS) guided biopsy. PATIENTS AND METHODS: 138 prostatic lesions in 23 patients were retrospectively assessed and analyzed with Trans rectal ultra-sound (TRUS) guided biopsy results. Those patients underwent multi parametric magnetic resonance (mp-MRI) with application of PI-RADS V2 reporting system. The sensitivity, specificity, validity, negative predictive value and positive predictive value were calculated for PI-RADS V2 reporting system compared to biopsy-proven pathological results. RESULTS: 92 out of 138 lesions were positive for Peripheral zone cancer prostate. PI-RADS V2 reporting system proved 88.04% sensitive & 93.4% specific for diagnosis of prostate cancer with negative predictive value & positive predictive value of 100%. CONCLUSION: Our results proved that mp-MRI of prostate using PI-RADS v2 scoring system had high sensitivity and specificity in diagnosis of prostate cancer and PI-RADS V2 scoring system using mp-MRI is recommended as a non-invasive diagnostic tool compared to TRUS guided biopsy. Elsevier 2017-03-21 /pmc/articles/PMC5369010/ /pubmed/28377946 http://dx.doi.org/10.1016/j.ejro.2017.02.001 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Dola, Eman F. Nakhla, Osama L. Genidi, Eman A.SH Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer |
title | Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer |
title_full | Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer |
title_fullStr | Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer |
title_full_unstemmed | Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer |
title_short | Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer |
title_sort | assessing the validity of prostate imaging reporting and data system version 2 (pi-rads v2) scoring system in diagnosis of peripheral zone prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369010/ https://www.ncbi.nlm.nih.gov/pubmed/28377946 http://dx.doi.org/10.1016/j.ejro.2017.02.001 |
work_keys_str_mv | AT dolaemanf assessingthevalidityofprostateimagingreportinganddatasystemversion2piradsv2scoringsystemindiagnosisofperipheralzoneprostatecancer AT nakhlaosamal assessingthevalidityofprostateimagingreportinganddatasystemversion2piradsv2scoringsystemindiagnosisofperipheralzoneprostatecancer AT genidiemanash assessingthevalidityofprostateimagingreportinganddatasystemversion2piradsv2scoringsystemindiagnosisofperipheralzoneprostatecancer |